Joyce A O'Shaughnessy

Summary

Affiliation: US Oncology
Country: USA

Publications

  1. pmc Cell line derived multi-gene predictor of pathologic response to neoadjuvant chemotherapy in breast cancer: a validation study on US Oncology 02-103 clinical trial
    Kui Shen
    Department of Product Development, Precision Therapeutics, Inc, 2516 Jane Street, Pittsburgh, PA 15203, USA
    BMC Med Genomics 5:51. 2012
  2. pmc Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis
    Joyce O'Shaughnessy
    Baylor Sammons Cancer Center, Texas Oncology and The US Oncology Network, 3410 Worth Street, Ste 400, Dallas, TX 75246, USA
    Breast Cancer Res Treat 138:829-37. 2013
  3. pmc Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer
    Joyce A O'Shaughnessy
    Baylor Sammons Cancer Center, Texas Oncology, US Oncology, 3535 Worth Street, Collins 5, Dallas, Texas 75246, USA
    Oncologist 17:476-84. 2012
  4. ncbi request reprint Fulvestrant: clinical application of an estrogen receptor downregulator
    Michael Torosian
    Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Clin Ther 24:A31-40. 2002
  5. doi request reprint Iniparib plus chemotherapy in metastatic triple-negative breast cancer
    Joyce O'Shaughnessy
    Baylor Charles A Sammons Cancer Center, Dallas, TX 75246, USA
    N Engl J Med 364:205-14. 2011
  6. ncbi request reprint Management of febrile neutropenia and cardiac toxicity in the adjuvant treatment of breast cancer
    Joyce A O'Shaughnessy
    Baylor Charles A Sammons Cancer Center, 3535 Worth Street, Dallas, TX 75246, USA
    Clin Breast Cancer 8:S11-21. 2007
  7. doi request reprint RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer
    Joyce A O'Shaughnessy
    Baylor Charles A Sammons Cancer Center, Baylor University Medical Center, Texas Oncology, P A, US Oncology, Dallas, TX, USA
    Clin Breast Cancer 8:370-3. 2008
  8. doi request reprint Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes
    Joanne L Blum
    Baylor Charles A Sammons Cancer Center, Dallas, Texas, USA
    Clin Breast Cancer 7:850-6. 2007
  9. doi request reprint Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer
    Nicholas J Robert
    US Oncology Research, Inc, The Woodlands, TX, USA
    Breast Cancer Res Treat 126:101-8. 2011
  10. ncbi request reprint Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy
    Joanne L Blum
    US Oncology Research, Inc, Houston, TX, USA
    Clin Breast Cancer 7:465-70. 2007

Collaborators

Detail Information

Publications41

  1. pmc Cell line derived multi-gene predictor of pathologic response to neoadjuvant chemotherapy in breast cancer: a validation study on US Oncology 02-103 clinical trial
    Kui Shen
    Department of Product Development, Precision Therapeutics, Inc, 2516 Jane Street, Pittsburgh, PA 15203, USA
    BMC Med Genomics 5:51. 2012
    ....
  2. pmc Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis
    Joyce O'Shaughnessy
    Baylor Sammons Cancer Center, Texas Oncology and The US Oncology Network, 3410 Worth Street, Ste 400, Dallas, TX 75246, USA
    Breast Cancer Res Treat 138:829-37. 2013
    ..In each trial, ORR was significantly higher for nab-paclitaxel versus the comparator taxane among patients with visceral dominant metastases...
  3. pmc Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer
    Joyce A O'Shaughnessy
    Baylor Sammons Cancer Center, Texas Oncology, US Oncology, 3535 Worth Street, Collins 5, Dallas, Texas 75246, USA
    Oncologist 17:476-84. 2012
    ..Here, we review the available data on capecitabine as a single agent for first-line treatment of patients with human epidermal growth factor receptor 2-negative MBC...
  4. ncbi request reprint Fulvestrant: clinical application of an estrogen receptor downregulator
    Michael Torosian
    Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Clin Ther 24:A31-40. 2002
  5. doi request reprint Iniparib plus chemotherapy in metastatic triple-negative breast cancer
    Joyce O'Shaughnessy
    Baylor Charles A Sammons Cancer Center, Dallas, TX 75246, USA
    N Engl J Med 364:205-14. 2011
    ..Triple-negative breast cancers have inherent defects in DNA repair, making this cancer a rational target for therapy based on poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition...
  6. ncbi request reprint Management of febrile neutropenia and cardiac toxicity in the adjuvant treatment of breast cancer
    Joyce A O'Shaughnessy
    Baylor Charles A Sammons Cancer Center, 3535 Worth Street, Dallas, TX 75246, USA
    Clin Breast Cancer 8:S11-21. 2007
    ..This article discusses therapeutic strategies that can reduce life-threatening cardiac toxicity and febrile neutropenia resulting from adjuvant breast cancer therapy...
  7. doi request reprint RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer
    Joyce A O'Shaughnessy
    Baylor Charles A Sammons Cancer Center, Baylor University Medical Center, Texas Oncology, P A, US Oncology, Dallas, TX, USA
    Clin Breast Cancer 8:370-3. 2008
  8. doi request reprint Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes
    Joanne L Blum
    Baylor Charles A Sammons Cancer Center, Dallas, Texas, USA
    Clin Breast Cancer 7:850-6. 2007
    ..We examined albumin-bound paclitaxel (100 mg/m2 or 125 mg/m2 administered weekly) to determine the antitumor activity in patients with MBC whose disease progressed despite conventional taxane therapy...
  9. doi request reprint Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer
    Nicholas J Robert
    US Oncology Research, Inc, The Woodlands, TX, USA
    Breast Cancer Res Treat 126:101-8. 2011
    ..Grade 1/2 alopecia was seen in 8% of patients. This phase II study of dose-dense, single-agent pemetrexed showed moderate activity in the first-line setting with acceptable toxicity and no significant alopecia...
  10. ncbi request reprint Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy
    Joanne L Blum
    US Oncology Research, Inc, Houston, TX, USA
    Clin Breast Cancer 7:465-70. 2007
    ....
  11. ncbi request reprint Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer
    Joyce A O'Shaughnessy
    Baylor Charles A Sammons Cancer Center, Dallas, Texas 75246, USA
    Clin Breast Cancer 5:142-7. 2004
    ..The combination of trastuzumab plus gemcitabine appears to be well tolerated and effective for patients with HER2-positive MBC previously treated with chemotherapy...
  12. ncbi request reprint Capecitabine/Taxane combination therapy: evolving clinical utility in breast cancer
    Joyce A O'Shaughnessy
    Baylor Charles A Sammons Cancer Center, Dallas, TX 75246, USA
    Clin Breast Cancer 7:42-50. 2006
    ..Several ongoing randomized adjuvant and neoadjuvant clinical trials are assessing the clinical utility of capecitabine/taxane combinations in early-stage and locally advanced breast cancer...
  13. ncbi request reprint Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer
    Stephen E Jones
    US Oncology Research, Inc, Texas Oncology, Dallas, TX 75246, USA
    J Clin Oncol 24:5381-7. 2006
    ..In 1997, we initiated a randomized adjuvant trial of TC compared with standard-dose AC with a primary end point of disease-free survival (DFS)...
  14. ncbi request reprint Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer
    Joyce A O'Shaughnessy
    Texas Oncology, PA, USA
    Clin Breast Cancer 6:143-9. 2005
    ..This phase II study evaluated the efficacy, safety, and health outcomes of pemetrexed treatment in heavily pretreated patients with advanced breast cancer...
  15. doi request reprint A phase II trial of pemetrexed and gemcitabine in patients with metastatic breast cancer who have received prior taxane therapy
    John Pippen
    USO, Texas Oncology, Baylor Sammons Cancer Center, Dallas, TX 75246, USA
    Clin Breast Cancer 10:148-53. 2010
    ..This phase II trial assessed efficacy and safety of pemetrexed plus gemcitabine to treat metastatic or locally advanced breast cancer in patients previously treated with taxanes...
  16. ncbi request reprint Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy
    Joyce A O'Shaughnessy
    Baylor Charles A Sammons Cancer Center, Dallas, TX 75246, USA
    Clin Breast Cancer 5:439-46. 2005
    ..Epoetin alfa therapy was well tolerated. These data suggest that epoetin alfa may have attenuated the cognitive impairment and fatigue that occurred during adjuvant breast cancer chemotherapy...
  17. ncbi request reprint The evolving role of capecitabine in breast cancer
    Joyce A O'Shaughnessy
    Baylor Charles A Sammons Cancer Center, US Oncology, Dallas, TX 75246, USA
    Clin Breast Cancer 4:S20-5. 2003
    ..This article is an overview of published studies of capecitabine in MBC and the studies that are planned or have been proposed to evaluate capecitabine as adjuvant therapy for breast cancer...
  18. ncbi request reprint Chemotherapy-induced cognitive dysfunction: a clearer picture
    Joyce A O'Shaughnessy
    Baylor Sammons Cancer Center, US Oncology, 3535 Worth Street, Collins Building 5th Floor, Dallas, TX 75246, USA
    Clin Breast Cancer 4:S89-94. 2003
    ..Ongoing and future studies will determine whether epoetin alfa can provide neuroprotection with respect to the development of cognitive dysfunction in patients undergoing adjuvant chemotherapy treatment for breast cancer...
  19. ncbi request reprint Phase II trial of weekly docetaxel/ gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer
    Joyce A O'Shaughnessy
    US Oncology, Dallas, TX 75246, USA
    Clin Breast Cancer 6:505-10. 2006
    ..A phase II study evaluated weekly docetaxel/gemcitabine as first-line chemotherapy for locally recurrent or metastatic breast cancer in a multicenter community oncology practice setting...
  20. doi request reprint Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer
    David Loesch
    US Oncology Research, Inc, Houston, TX, USA
    Clin Breast Cancer 8:178-86. 2008
    ..This phase II trial studied the efficacy and safety of gemcitabine/carboplatin with or without trastuzumab in patients with MBC...
  21. doi request reprint Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer
    John W Smith
    US Oncology Research, Inc, The Woodlands, TX, USA
    Breast Cancer Res Treat 118:361-7. 2009
    ..This phase II study demonstrates oral satraplatin has limited activity as a single agent for MBC. Satraplatin, at a lower dose used in this study, could be combined with other chemotherapy agents in future trials in breast cancer...
  22. ncbi request reprint Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer
    Aman Buzdar
    M D Anderson Cancer Center and US Oncology Research, Houston, and Baylor Sammons Cancer Center and Texas Oncology, Dallas, TX 77030, USA
    J Clin Oncol 21:1007-14. 2003
    ....
  23. ncbi request reprint Pemetrexed: a promising new treatment for breast cancer
    Joyce A O'Shaughnessy
    Baylor Sammons Cancer Center, US Oncology, Dallas, TX, USA
    Semin Oncol 29:36-41. 2002
    ....
  24. doi request reprint The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer
    Cynthia R Osborne
    Baylor Sammons Cancer Center, Dallas, TX 75246, USA
    Breast Cancer Res Treat 116:521-7. 2009
    ..The addition of HT to tamoxifen therapy does not ameliorate tamoxifen-induced vasomotor symptoms. Tamoxifen associated weight gain, however, may be lessened by the addition of HT...
  25. ncbi request reprint Ductal lavage and the clinical management of women at high risk for breast carcinoma: a commentary
    Joyce A O'Shaughnessy
    Baylor Sammons Cancer Center, Dallas, Texas 75246, USA
    Cancer 94:292-8. 2002
  26. ncbi request reprint Pegylated liposomal doxorubicin in the treatment of breast cancer
    Joyce A O'Shaughnessy
    Charles A Sammons Cancer Center, US Oncology, Baylor University Medical Center, Collins Building, 3535 Worth Street, Dallas, TX 75246, USA
    Clin Breast Cancer 4:318-28. 2003
    ..Owing to its comparable efficacy and favorable safety profile, pegylated liposomal doxorubicin may be a useful alternative to conventional doxorubicin, as well as other agents commonly used in the treatment of breast cancer...
  27. ncbi request reprint Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development
    Joyce A O'Shaughnessy
    Baylor Sammons Cancer Center, US Oncology, Collins 5, 3535 Worth Street, Dallas, TX 75246, USA
    Clin Cancer Res 8:314-46. 2002
    ..The IEN Task Force proposes several clinical trial designs that provide practical and feasible approaches to the rapid development of new agents to treat and prevent precancer...
  28. ncbi request reprint Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy
    Joyce A O'Shaughnessy
    Baylor Sammons Cancer Center, US Oncology, Dallas, Texas 75246, USA
    Clin Breast Cancer 3:S116-20. 2002
    ..We report here the preliminary results of this pilot clinical trial...
  29. ncbi request reprint Ductal lavage: clinical utility and future promise
    Joyce A O'Shaughnessy
    Breast Cancer Research, Baylor Sammons Cancer Center, US Oncology, 3535 Worth Street, Collins 5, Dallas, TX 75246, USA
    Surg Clin North Am 83:753-69, vii. 2003
    ..Aspects discussed include the rationale for use of ductal lavage, identification of appropriate candidates for the procedure, clinical implications, ongoing evaluation of the procedure, and its future utility...
  30. ncbi request reprint Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer
    Steven A Limentani
    Carolinas Hematology Oncology Associates, The Blumenthal Cancer Center, University of North Carolina, Charlotte, NC 28203, USA
    J Clin Oncol 25:1232-8. 2007
    ..To evaluate the combination of docetaxel, vinorelbine, and trastuzumab as neoadjuvant therapy for human epidermal growth factor receptor 2 (HER2)--overexpressing breast cancer...
  31. pmc Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer
    Catherine M Bender
    University of Pittsburgh School of Nursing, Pittsburgh, PA 15261, USA
    Menopause 14:995-8. 2007
    ..We hypothesized, therefore, that anastrozole would have a more profound effect on cognitive function than tamoxifen, a mixed estrogen agonist/antagonist...
  32. doi request reprint Cancer treatment-induced bone loss: pathophysiology and clinical perspectives
    Adam M Brufsky
    University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Oncologist 13:187-95. 2008
    ..Such agents have the potential to delay or prevent CTIBL in patients receiving hormonal therapies...
  33. ncbi request reprint Cognitive impairment associated with adjuvant therapy in breast cancer
    Catherine M Bender
    University of Pittsburgh School of Nursing, Victoria Building, Suite 415, Pittsburgh, PA 15261, USA
    Psychooncology 15:422-30. 2006
    ..In conclusion, adjuvant chemotherapy in women with breast cancer can be associated with deteriorations in memory and this may persist over time. The addition of tamoxifen may lead to more widespread memory deficits...
  34. pmc What do perceived cognitive problems reflect?
    Catherine M Bender
    University of Pittsburgh School of Nursing, 3500 Victoria Street, Suite 415, Pittsburgh, PA 15261, USA
    J Support Oncol 6:238-42. 2008
    ..At a minimum, our results indicated that women's complaints of cognitive problems should prompt additional assessment to clarify the bases of the problem and initiate appropriate intervention...
  35. ncbi request reprint Bone health issues in women with early-stage breast cancer receiving aromatase inhibitors
    Adam M Brufsky
    Magee Womens Hospital of University of Pittsburgh Medical Center, Suite 4628, 300 Halket Street, Pittsburgh, PA 15213, USA
    Curr Oncol Rep 10:18-26. 2008
    ..However, several large studies to clarify the role of bisphosphonates in maintaining or improving bone health in these women are under way...
  36. doi request reprint Histopathologic variables predict Oncotype DX recurrence score
    Melina B Flanagan
    Department of Pathology, Magee Women s Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Mod Pathol 21:1255-61. 2008
    ..Although the Oncotype DX Recurrence Score holds potential, further validation of its independent value beyond that of histopathologic analysis is necessary before it can be implemented in clinical decision making...
  37. ncbi request reprint Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors
    Adam M Brufsky
    Magee Women s Hospital of the University of Pittsburgh Medical Center, 300 Halket Street, Pittsburgh, PA 15213, USA
    Clin Breast Cancer 8:S22-34. 2007
    ..Until these data become available, balancing the safety concerns with the potential benefits of I.V. bisphosphonates to minimize or prevent AI-induced bone loss in women with early-stage breast cancer is required...
  38. ncbi request reprint The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events
    Margaret Q Rosenzweig
    Department of Acute Tertiary Care, University of Pittsburgh School of Nursing, Pittsburgh, Pennsylvania 15261, USA
    J Pain Symptom Manage 27:185-90. 2004
    ..This may relate to the administration of r-HuEPO in this high-risk population, but the small sample size and possible predisposing risk factors preclude definitive conclusions...
  39. ncbi request reprint Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer
    Steven A Limentani
    Carolinas Hematology Oncology Associates, Charlotte, NC 28203, USA
    Clin Breast Cancer 6:511-7. 2006
    ..The purpose of this study was to evaluate the combination of docetaxel plus vinorelbine as neoadjuvant chemotherapy for stage II/III locally advanced breast cancer...
  40. ncbi request reprint Single-fraction radiosurgery for the treatment of spinal breast metastases
    Peter C Gerszten
    Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA
    Cancer 104:2244-54. 2005
    ..This study evaluated the clinical efficacy of the treatment of spinal breast carcinoma metastases with a single-fraction radiosurgical technique...
  41. ncbi request reprint Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers
    Ramesh K Ramanathan
    Molecular Therapeutics Drug Discovery Program, Biostatistics Department, Graduate School of Public Health, and Biostatistics Facility, University of Pittsburgh Cancer Institute, PA 15232, USA
    Clin Cancer Res 11:3385-91. 2005
    ..We did a phase I study of 17AAG to establish the dose-limiting toxicity and maximum tolerated dose and to characterize 17AAG pharmacokinetics and pharmacodynamics...